CR20140086A - Tratamientos de combinación para hepatitis c - Google Patents

Tratamientos de combinación para hepatitis c

Info

Publication number
CR20140086A
CR20140086A CR20140086A CR20140086A CR20140086A CR 20140086 A CR20140086 A CR 20140086A CR 20140086 A CR20140086 A CR 20140086A CR 20140086 A CR20140086 A CR 20140086A CR 20140086 A CR20140086 A CR 20140086A
Authority
CR
Costa Rica
Prior art keywords
hepatitis
combination treatments
combination
compositions
iii
Prior art date
Application number
CR20140086A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR20140086A publication Critical patent/CR20140086A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos y composicionesfarmacéuticas para el tratamiento de Hepatitis C en un ser humanoque lo necesite, los cuales comprenden administrar un compuesto de la fórmula (I), (II), (III), (IV), (V), o (VI) descrito en la presente, o una sal farmacéuticamente aceptable del mismo, en combinación con uno o más agentes terapéuticos adicionales para Hepatitis C.
CR20140086A 2011-08-24 2014-02-24 Tratamientos de combinación para hepatitis c CR20140086A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US201261617813P 2012-03-30 2012-03-30

Publications (1)

Publication Number Publication Date
CR20140086A true CR20140086A (es) 2014-05-02

Family

ID=47746891

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140086A CR20140086A (es) 2011-08-24 2014-02-24 Tratamientos de combinación para hepatitis c

Country Status (18)

Country Link
US (1) US20140234253A1 (es)
EP (1) EP2747569A4 (es)
JP (2) JP2014527061A (es)
KR (1) KR20140065427A (es)
CN (1) CN103917095A (es)
AU (1) AU2012298750A1 (es)
BR (1) BR112014004182A2 (es)
CA (1) CA2845321A1 (es)
CL (1) CL2014000428A1 (es)
CO (1) CO6890100A2 (es)
CR (1) CR20140086A (es)
EA (1) EA201490254A1 (es)
HK (1) HK1198869A1 (es)
IL (1) IL230844A0 (es)
MX (1) MX2014002171A (es)
PH (1) PH12014500386A1 (es)
SG (1) SG2014010490A (es)
WO (1) WO2013028953A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473056A4 (en) * 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
SG10201606646RA (en) 2011-08-17 2016-09-29 Glaxosmithkline Llc Therapeutic methods
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112015025766A2 (pt) 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc derivado de nucleosídeo altamente ativo para o tratamento de hcv
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015005901A1 (en) * 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
EP3091010A4 (en) * 2013-12-31 2017-10-04 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
CN106279122A (zh) * 2014-01-21 2017-01-04 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
EP3218485A1 (en) * 2014-11-10 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions for hepatitis c
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业（浙江）有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010080874A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
RS56654B8 (sr) * 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
EP2473056A4 (en) * 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG181797A1 (en) * 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs

Also Published As

Publication number Publication date
CA2845321A1 (en) 2013-02-28
JP2017165746A (ja) 2017-09-21
HK1198869A1 (en) 2015-06-19
KR20140065427A (ko) 2014-05-29
EP2747569A1 (en) 2014-07-02
JP2014527061A (ja) 2014-10-09
BR112014004182A2 (pt) 2017-03-14
IL230844A0 (en) 2014-03-31
EP2747569A4 (en) 2015-07-08
WO2013028953A1 (en) 2013-02-28
US20140234253A1 (en) 2014-08-21
AU2012298750A1 (en) 2014-03-13
PH12014500386A1 (en) 2019-10-07
CN103917095A (zh) 2014-07-09
SG2014010490A (en) 2014-04-28
CL2014000428A1 (es) 2014-08-01
EA201490254A1 (ru) 2014-07-30
MX2014002171A (es) 2014-04-25
CO6890100A2 (es) 2014-03-10

Similar Documents

Publication Publication Date Title
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2014015185A (es) Derivados deuterados de ruxolitinib.
AR101740A1 (es) Terapia de combinación y composiciones
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
MX2015014097A (es) Tratamiento de cancer empleando terapias combinadas de coenzima q10.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
UY35211A (es) Compuestos tricíclicos
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
UY35209A (es) Compuestos tricíclicos
CR20140075A (es) Métodos terapéuticos
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
DOP2013000206A (es) Inhibidores de la peptido desformilasa
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica